The current advanced pipeline includes Estetrol (E4) and Zona Pellucida (ZP) immunotherapy.
Estetrol (E4) is a fetal estrogen suitable for oncological applications including breast cancer and prostate cancer. The E4 program has successfully reached Phase II. At present clinical studies are ongoing for the treatment of breast cancer in Germany and for prostate cancer in the Netherlands. The ZP program opens a promising way to discover a new immuno-therapy for several cancers, including ovarian cancer, prostate cancer, breast cancer, colorectal cancer and non-small cell lung cancer. The preclinical development of the ZP program is currently ongoing. The program for ovarian cancer has been licensed out to HRA Pharma SA, Paris (France) in 2014. Pantarhei is developing the other applications.